Use of cotton rats to evaluate the efficacy of antivirals in treatment of measles virus infections

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 5, 2000, Pages 1146-1152

  Wyde, Philip R ^a   Moore Poveda, Donna K ^a   De Clercq, Erik ^b   Neyts, Johan ^b   Matsuda, Akira ^c   Minakawa, Noriaki ^c   Guzman, Efrain ^a   Gilbert, Brian E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c HOKKAIDO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 ETHYNYL 4 IMIDAZOLECARBOXAMIDE 1 RIBOSIDE; RIBAVIRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY TITER; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; DRUG SAFETY; MEASLES; MEASLES VIRUS; NONHUMAN; PRIORITY JOURNAL; RAT; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; DISEASE MODELS, ANIMAL; MEASLES; MEASLES VIRUS; MICE; MICROBIAL SENSITIVITY TESTS; POLYMERS; RATS; RIBAVIRIN; RIBONUCLEOSIDES; SIGMODONTINAE; SULFONIC ACIDS; TUMOR CELLS, CULTURED;

EID: 0034094277     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.5.1146-1152.2000     Document Type: Article

References (39)

1. Ahmed, S. A., R. M. Gogal, Jr., and J. E. Walsh. 1994. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to H3-thyimidine incorporation assay. J. Immuriol. Methods 170:211-224.
2. Albrecht, P., D. Lorenz, M. J. Klutch, J. H. Vickers, and F. A. Ennis. 1980. Fatal measles infection in marmosets pathogenesis and prophylaxis. Infect. Immun. 27:969-978.
3. Atmar, R. L., J. A. England, and H. Hammill. 1992. Complications of measles during pregnancy. Clin. Infect. Dis. 14:217-226.
4. Banks, G., and H. Fernandez. 1980. Clinical use of ribavirin in measles: a summarized review, p. 203-209. In A. D. Smith, V. Knight, and J. A. D. Smith (ed.), Clinical applications of ribavirin. Academic Press, Inc., New York, N.Y.
5. Blake, F. G., and J. D. Trask, Jr. 1921. Studies on measles. I. Susceptibility of monkeys to the virus of measles. J. Exp. Med. 33:385-412.
6. Children's Vaccine Initiative. 1999. A plethora of hi-tech vaccines - genetic, edible, sugar glass, and more, p. 1-23. In J. Maurice (ed.). CVI Forum No. 18. World Health Organization, Geneva, Switzerland.
7. Cutts, F. T., A. M. Henao-Restrepo, and J. M. Olive. 1999. Measles elimination: progress and challenges. Vaccine 17:S47-S52.
8. De Clercq, E., M. Cools, J. Balzarini, R. Snoeck, G. Andrei, M. Hosoya, S. Shigeta, T. Ueda, N. Minakawa, and A. Matsuda. 1991. Antiviral activities of 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide and related compounds. Antimicrob. Agents Chemother. 35:679-684.
9. Department of Vaccines and Other Biologicals. 1999. Measles control, p. 59-64. In Vaccine and biologicals annual report, 1998. World Health Organization, Geneva, Switzerland.
10. Feldstein, T. J., J. L. Swegarden, G. F. Atwood, and C. D. Peterson. 1995. Ribavirin therapy: implementation of hospital guidelines and effect on usage and cost of therapy. Pediatrics 96:14-17.
11. Forni, A. L., N. W. Schluger, and R. B. Roberts. 1994. Severe measles pneumonitis in adults: evaluation of clinical characteristics and therapy with intravenous ribavirin. Clin. Infect. Dis. 19:454-462.
12. Gilbert, B. E., P. R. Wyde, M. W. Ambrose, S. Z. Wilson, and V. Knight. 1992. Further studies with short duration ribavirin aerosol for the treatment of influenza virus infection in mice and respiratory syncytial virus infection in cotton rats. Antivir. Res. 17:33-42.
13. Gururangan, S., R. F. Stevens, and D. J. Morris. 1990. Ribavirin response in measles pneumonia. J. Infect. Dis. 20:219-221.
14. Guyton, A. C. 1947. Measurement of the respiratory volumes of laboratory animals. Am. J. Physiol. 150:70-77.
15. Hall, W. C., R. M. Kovatch, P. J. Herman, and J. G. Fox. 1971. Pathology of measles in rhesus monkeys. Vet. Pathol. 8:307-319.
16. Hoffmann, S. H., M. J. Wade, J. A. Staffa, D. B. McGregor, M. Holmstrom, and A. D. Dayan. 1987. Dominant lethal study of ribavirin in male rats. Mutat. Res. 188:29-34.
17. Huffman, J. H., R. W. Sidwell, G. P. Khare, J. T. Witkowski, L. B. Allen, and R. K. Robbins. 1973. In vitro effect of 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (virazole, ICN 1229) on deoxyribonucleic acid and ribonucleic acid viruses. Antimicrob. Agents Chemother. 3:235-241.
18. Ikeda, S., J. Neyts, S. Verma, A. Wickramasinghe, P. Mohan, and E. De Clercq. 1994. In vitro and in vivo inhibition of ortho- and paramyxovirus infections by a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion. Antimicrob. Agents Chemother. 38:256-259.
19. Kernahan, J., J. McQuillin, and A. W. Craft. 1999. Measles in children who have malignant disease. Bone Marrow Transplant. 295:15-18.
20. Malvoisin, E., and F. Wild. 1990. Contribution of measles virus fusion protein in protective immunity: anti-F monoclonal antibodies neutralize virus infectivity and protect mice against challenge. J. Virol. 64:5160-5162.
21. Marquardt, E. D. 1995. Cost of ribavirin therapy for respiratory syncytial virus infection. J. Pediatr. 126:847.
22. May, K. R. 1973. The collison nebulizer: description, performance and application. Aerosol Sci. 4:235-243.
23. Minakawa, N., T. Takeda, T. Sasaki, A. Matsuda, and T. Ueda. 1991. Synthesis and antineoplastic activity of 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide (EICAR) and its derivatives. J. Med. Chem. 34:778-786.
24. Minakawa, N., and A. Matsuda. 1999. Mechanism-based design and inosine 5′-monophosphate dehydrogenase inhibitors: synthesis and biological activities of 5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide (EICAR) and its derivatives. Curr. Med. Chem. 6:615-628.
25. Niewiesk, S. 1999. Cotton rats (Sigmodon hispidus): an animal model to study the pathogenesis of measles virus infection. Immunol. Lett. 65:47-50.
26. Ottolini, M. G., and V. G. Hemming. 1997. Prevention and treatment recommendations for respiratory syncytial virus infection - background and clinical experience 40 years after discovery. Drugs 54:867-884.
27. Ross, L. A., S. K. Kwang, W. H. Mason, Jr., and E. Gomperts. 1984. Successful treatment of disseminated measles in a patient with acquired immunodeficiency syndrome: consideration of antiviral and passive immunotherapy. Am. J. Med. 88:313-314.
28. Shigeta, S., S. Mori, M. Baba, M. Ito, K. Honzumi, K. Nakamura, H. Oshitani, Y. Numazaki, A. Matsuda, T. Obara, S. Shuto, and E. De Clercq. 1992. Antiviral activities of ribavirin, 5-ethynyl-1-β-D-ribofuranosylimidazole-4-carboxamide, and 6′-(R)-6′-C-methylneplanocin A against several ortho- and paramyxoviruses. Antimicrob. Agents Chemother. 36:435-439.
29. Sidwell, R. W., J. H. Huffman, G. P. Khare, L. B. Allen, J. T. Witkowski, and R. K. Robins. 1972. Broad-spectrum antiviral activity of virazole: 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177:705-706.
30. Stogner, S. W., J. W. King, C. Black-Payne, and J. Bocchini. 1993. Ribavirin and intravenous immune globulin therapy for measles pneumonia in HIV infection. South. Med. J. 141:1415-1418.
31. Sun, C.-S., P. R. Wyde, S. Z. Wilson, and V. Knight. 1984. Efficacy of aerosolized recombinant interferons against vesicular stomatitis virus-induced lung infection in cotton rats. J. Interferon Res. 4:449-459.
32. Voytik-Harbin, S. L., A. O. Brightman, B. Waisner, C. H. Lamar, and S. F. Badylak. 1998. Application and evaluation of the alamarBlue assay for cell growth and survival of fibroblasts. In Vitro Cell Dev. Biol. Anim. 34:239-246.
33. Wilson, S. Z., B. E. Gilbert, J. M. Quarles, V. Knight, H. W. McClung, R. V. Moore, and R. B. Couch. 1984. Treatment of influenza A (H1N1) virus infection with ribavirin aerosol. Antimicrob. Agents Chemother. 26:200-203.
34. Wilson, S. Z., V. Knight, R. Moore, and E. W. Larson. 1979. Amantadine small-particle aerosol: generation and delivery to man. Proc. Soc. Exp. Biol. Med. 161:350-354.
35. Wilson, S. Z., V. Knight, P. R. Wyde, S. Drake, and R. B. Couch. 1980. Amantadine and ribavirin aerosol treatment of influenza A and B infection in mice. Antimicrob. Agents Chemother. 17:642-648.
36. Wyde, P. R., M. W. Ambrose, H. L. Meyer, and B. E. Gilbert. 1990. Toxicity and antiviral activity of LY253963 against respiratory syncytial and parainfluenza type 3 viruses in tissue culture and in cotton rats. Antivir. Res. 14:237-247.
37. Wyde, P. R., M. W. Ambrose, T. G. Voss, H. L. Meyer, and B. E. Gilbert. 1992. Measles virus replication in lungs of hispid cotton rats following intranasal inoculation. Proc. Soc. Exp. Biol. Med. 201:80-87.
38. Wyde, P. R., D. K. Moore-Poveda, N. J. Daley, and H. Oshitani. 1999. Replication of clinical measles virus strains in hispid cotton rats. Proc. Soc. Exp. Biol. Med. 221:53-62.
39. Wyde, P. R., S. Z. Wilson, R. Petrella, and B. E. Gilbert. 1987. Efficacy of high dose-short duration ribavirin aerosol in the treatment of respiratory syncytial virus infected cotton rats and influenza B virus infected mice. Antivir. Res. 7:211-220.